Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study.

CONCLUSION: Switching patients with IBD from originator to biosimilar infliximab is safe and non-inferior to continuing treatment with originator infliximab. Moreover, the introduction of biosimilar infliximab, by increasing market competition, has resulted in substantial cost savings for the Pharmaceutical Benefits Scheme. PMID: 33070332 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33070332?dopt=Abstract

Source: Med J Aust - October 17, 2020 Category: General Medicine Authors: Haifer C, Srinivasan A, An YK, Picardo S, van Langenberg D, Menon S, Begun J, Ghaly S, Thin L Tags: Med J Aust Source Type: research